PEAK6 Investments’s Alexion Pharmaceuticals ALXN Stock Holding History

PEAK6 Investments’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-62,400	Closed	-$9.75M	–	5839
2020 Q4	$9.75M	Buy	62,400 +6,900	+12%	+$887K	0.02%	687
2020 Q3	$6.35M	Sell	55,500 -4,000	-7%	-$432K	0.02%	826
2020 Q2	$6.68M	Sell	59,500 -98,500	-62%	-$10.5M	0.02%	659
2020 Q1	$14.2M	Buy	158,000 +77,400	+96%	+$7.6M	0.08%	237
2019 Q4	$8.72M	Sell	80,600 -53,000	-40%	-$5.67M	0.05%	409
2019 Q3	$13.1M	Buy	133,600 +42,800	+47%	+$4.82M	0.08%	264
2019 Q2	$11.9M	Sell	90,800 -12,400	-12%	-$1.6M	0.08%	302
2019 Q1	$14M	Buy	103,200 +13,000	+14%	+$1.62M	0.08%	261
2018 Q4	$8.78M	Sell	90,200 -80,600	-47%	-$9.53M	0.06%	383
2018 Q3	$23.7M	Buy	+170,800	New	+$21.4M	0.1%	192

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PEAK6 Investments's ALXN Position: Q4 2020 in Review

PEAK6 Investments sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 8,907 shares — an estimated $1.14M sold.

PEAK6 Investments first reported a position in ALXN in Q3 2018 and held it in 9 quarters. The position peaked at $6.87M in Q1 2020. 825 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

PEAK6 Investments reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
PEAK6 Investments sold 8,907 Alexion Pharmaceuticals shares in Q4 2020, an estimated $1.14M.
PEAK6 Investments first reported a position in Alexion Pharmaceuticals in Q3 2018 and held it in 9 quarters.
PEAK6 Investments's Alexion Pharmaceuticals position peaked at $6.87M in Q1 2020.
825 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on PEAK6 Investments's 13F filing for Q4 2020, filed 12 Feb 2021.